BCA
GLUE icon

Berman Capital Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

Berman Capital Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$0 Buy
+40
New +$1.15K ﹤0.01% 2126

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Berman Capital Advisors's GLUE Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in Monte Rosa Therapeutics (GLUE) in Q3 2021: 40 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #2126 among its holdings.

56 funds tracked by Wall St. Rank hold GLUE as of Q3 2021.

  • Berman Capital Advisors held 40 shares of Monte Rosa Therapeutics worth $0 as of Q3 2021.
  • Monte Rosa Therapeutics was a new Berman Capital Advisors position in Q3 2021.
  • Monte Rosa Therapeutics made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #2126 holding.
  • 56 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.